Madrigal Pharmaceuticals stock consolidates above $530 amid patient and advocate outreach efforts

Traders Union
All News
Business & Wealth
Companies
Madrigal Pharmaceuticals down 2.44% today

Highlights

MDGL remains in a strong multi-timeframe uptrend, consistently trading above key short- and long-term support levels.
Technical indicators signal bullish momentum with positive MACD and supportive RSI, though overall trend strength is currently moderate.
Next week's projected trading corridor is $525–$560, with a greater than 80% probability of holding or moving higher barring a break of $530 support.

The company stated it looks forward to connecting with patients, advocates and healthcare professionals at the event. Madrigal Pharmaceuticals described the convention as educational and interactive.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish alignment as price holds above key moving averages

MDGL is trading at $539.98, sitting above the MA-20 ($531.45), MA-50 ($514.41), and MA-200 ($502.73), which confirms a strong bullish trend across short-, medium-, and long-term timeframes. The Ichimoku Kijun on D1 is at $515.17, placing it below the current price and marking immediate support. Near-term support is seen at the MA-20 ($531.45) with key support at the MA-50 ($514.41), while near-term resistance lies at the MA-5 cluster ($543.42–$546.95) and the next key resistance at the MA-10 EMA ($542.26) just above the current level.

Positive momentum moderates as consolidation follows intraday declines

Momentum remains moderately positive, as the MACD on D1 signals a buy but the ADX on D1 is neutral, indicating trend strength is relatively weak. RSI on D1 (60.02) and CCI (94.21) remain in supportive territory without clear overbought signals, while Stoch RSI is mid-range and BBP reads as overbought, suggesting buyer dominance but with a risk of short-term cooling. In today's session, the price has declined 2.44%, reflecting pronounced intraday selling pressure. Over the week, MDGL has fallen $13.50 (2.44%) from a previous close of $553.48, with the current price in the middle of its weekly range. Weekly volatility stands at 6.91%. The recent tone is consolidation after a pullback from highs.

Sideways bias as bullish signals outweigh downside risk

For the next week, the projected price corridor is $525–$560, normalized for recent volatility, keeping the outlook within roughly ±4% of the latest price and well above the 52-week low of $286.44 though below the recent peak of $615.00. Given all four of RSI-W1, ADX-W1, MACD-W1, and MA-50-W1 provide Buy signals, the probability of a further increase is very high (more than 80%), making a price decline much less likely. The baseline scenario expects MDGL to trade sideways within this corridor. A bullish breakout above resistance levels could target the high $550s, while a break below support near $530 would open space for a temporary dip toward the low $520s.

Earlier, analysts noted that Madrigal Pharmaceuticals continued to exhibit a strong bullish trend, though technical signals pointed to a potential pause or consolidation. In light of recent developments, traders should closely monitor for a shift in momentum that could establish the next decisive direction for MDGL.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.